European Journal of Pharmaceutics and Biopharmaceutics 78 (2011) 361–365

Contents lists available at ScienceDirect

European Journal of Pharmaceutics and Biopharmaceutics

journal homepage: www.elsevier.com/locate/ejpb

Research paper

Thiomers: Inhibition of cytochrome P450 activity

Javed Iqbal [a], Duangkamon Sakloetsakun [b], Andreas Bernkop-Schnürch [a,*]

[a] Department of Pharmaceutical Technology, University of Innsbruck, Innrain, Innsbruck, Austria
[b] Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

ARTICLE INFO

Article history:
Received 8 July 2010
Accepted in revised form 21 February 2011
Available online 27 February 2011

Keywords:
Thiomers
Cytochrome P450
CYP3A4
CYP2A6
Inhibition
Fluorescent probe assays

ABSTRACT

The aim of the present study was to investigate the potential of different thiolated polymers (thiomers) on the catalytic activity of CYP450s on one hand and to explore new inhibitors for CYP activity on the other hand. Several thiolated polymers including poly(acrylic acid)–cysteine (PAA–cysteine), chitosan–thioglycolic acid (chitosan–TGA), and thiolated PEG-*g*-PEI copolymer along with brij® 35, myrj® 52 and the well-established CYPP450 inhibitor verapamil were screened for their CYP3A4 and CYP2A6 inhibitory activity, and their IC_{50} values were determined. Both enzyme inhibition assays were performed in 96-well microtiter plates. 7-Benzyloxy-4-(trifluoromethyl)-coumarin (BFC) and 7-hydroxycoumarin (7-HC) were used as fluorescent substrates in order to determine CYP3A4 and CYP2A6 catalytic activity, respectively. All investigated compounds inhibited CYP3A4 as well as CYP2A6 activity. All tested (thiolated) polymers were found to be more potent inhibitors of CYP3A4 than of CYP2A6 catalytic activity. Apart from verapamil that is a known CYP3A4 inhibitor, brij® 35 and myrj® 52 were explored as potent inhibitors of CYP3A4 and CYP2A6 catalytic activity. Among the tested polymers, the rank order for CYP3A4 inhibition was PAA–cysteine (100 kDa) > brij® 35 > thiolated PEG-*g*-PEI copolymer (16 kDa) > myrj® 52 > PAA (100 kDa) > PAA–cysteine (450 kDa) > verapamil > PAA (450 kDa) > chitosan–TGA (150 kDa) > chitosan (150 kDa). On the other hand, the rank order of CYP2A6 inhibition was brij® 35 > PAA–cysteine (100 kDa) > chitosan–TGA (150 kDa) > PAA (100 kDa) > thiolated PEG-*g*-PEI copolymer (16 kDa) > PAA–cysteine (450 kDa) > chitosan (150 kDa) > verapamil > PAA (450 kDa) > myrj® 52. Thus, this study suggests that (thiolated) polymers display a promising potential to inhibit cytochrome P450s activity and might turn out to be potentially valuable tools for improving the oral bioavailability of actively secreted compounds by avoiding intestinal metabolism.

1. Introduction

Oral administration of drugs is strongly recommended because of its convenience, the relative low production costs, and the high level of patient compliance and safety. However, a noticeable percentage of drugs do not exhibit the characteristics required for oral administration. A prerequisite for a drug to be efficient after oral administration is that it mainly bypasses a series of physical and biochemical barriers in the gastrointestinal tract. Out of which an important element of barrier function is a large super family of heme-thiolate proteins, cytochrome P450s (CYP450s).

CYP450s isoenzymes play an important role in the phase I oxidative metabolism of structurally diverse xenobiotics, such as drugs, toxic chemicals, carcinogens as well as endobiotic chemicals including steroids, fatty acids, fat-soluble vitamins, and prostaglandins [1]. The ability of CYP450 to effectively limit the penetration of compounds into select tissues can profoundly influence the efficacy of a drug by restricting its interaction with the target site. Conversely, this same process may effectively prevent agents from reaching toxic levels in these protected tissues [2].

CYP3A4 is the most important drug-metabolizing enzyme belonging to CYP 3A family that metabolizes a wide variety of xenobiotics, endogenous substrates, and more than 50% of administrated drugs. Thus, it represents a major contributor in the reduced bioavailability of numerous drugs. On the other hand, human CYP2A6 is expressed predominantly in the liver, representing between 1% and 10% of total hepatic P450s and responsible for the metabolism of various clinically relevant compounds.

Over the past few years, thiolated polymers so-called thiomers that are obtained by the immobilization of thiol-bearing ligands onto the polymeric backbones have been introduced in the pharmaceutical literature. These thiolated polymers demonstrated not only improved mucoadhesive, controlled release and permeation-enhancing properties but also enzyme inhibitory properties [3]. Recently, Werle and Hoffer reported a significantly improved

* Corresponding author. Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Josef-Moeller-Haus, Innrain 52c, 6020 Innsbruck, Austria. Tel.: +43 512 507 5383; fax: +43 512 507 2933.
E-mail address: andreas.bernkop@uibk.ac.at (A. Bernkop-Schnürch).

0939-6411/$ - see front matter © 2011 Published by Elsevier B.V.
doi:10.1016/j.ejpb.2011.02.017

transmucosal transport of P-gp substrate rhodamine-123 (Rho-123) in the presence of thiolated chitosan as a result of P-gp efflux pump inhibition [4].

CYPs and P-gp are both expressed in the intestinal mucosa and function as a barrier to oral drug delivery either by transmembranal efflux or by metabolizing drugs. There is a noticeable overlap in the drugs that interact with these two proteins, and both proteins share many inhibitors, substrates, and inducers. For instance, previous studies provide evidence that CYPs are inhibited by amiodarone, ketoconazole, quinidine, and verapamil that are known to inhibit P-gp as well. [5,6].

It was therefore the aim of this study to evaluate the influence of different thiolated polymers on the catalytic activity of CYP450s on one hand and to explore new inhibitors for CYP activity on the other hand. For this purpose, several thiolated polymers along with brij® 35 and myrj® 52 in comparison with well-established cytochrome P450 inhibitor verapamil were screened for CYPs inhibitory activity, and their IC_{50} values were determined. CYP3A4 and CYP2A6 were chosen for CYP inhibition studies as these enzymes are jointly responsible for more than 60% of overall drug metabolism.

2. Materials and methods

2.1. Materials

Polyethylenimine (PEI) 600 Da was purchased from Polysciences. Homo-functional polyethylene glycol (OH-PEG-OH) 6000 Da was from Rapp Polymere GmbH, Germany. Hexamethylene diisocyanate (HMDI) and chitosan (from crab shell; degree of deacetylation >85%) were purchased from Fluka. (±)-Verapamil hydrochloride, γ-thiobutyrolactone, and thioglycolic acid (TGA) were purchased from Sigma. Coumarin, β-nicotinamide adenine dinucleotide phosphate reduced tetra(cyclohexylammonium) salt (NADPH), L-cysteine hydrochloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC), and poly(acrylic acid) (PAA) having molecular mass of 100 kDa and 450 kDa, respectively, were purchased from Sigma. 7-Benzyloxy-4-(trifluoromethyl)-coumarin (BFC), baculovirus-expressed human CYP3A4, and CYP2A6 supersomes were purchased from BD Biosciences Discovery Labware (Bedford, MA). All other reagents used were of analytical grade.

2.2. Methods

2.2.1. Polymers synthesis

2.2.1.1. Poly(acrylic acid)–cysteine (PAA–cysteine; 100 kDa and 450 kDa). PAA–cysteine conjugates (100 kDa and 450 kDa) were synthesized by the covalent attachment of cysteine to poly(acrylic acid) according to a method described previously [7]. Briefly, 1 g each of PAA 100 kDa and PAA 450 kDa were hydrated separately in demineralized water, and the pH value of the PAA solutions was adjusted to 6 by the addition of 5 M NaOH. Then, EDAC in the final concentration of 200 mM was added in order to activate the carboxylic acid moieties of each of the hydrated polymers. After 20 min of incubation under stirring at room temperature, 1 g of L-cysteine was added to each of the hydrated PAA solutions and the pH was readjusted to 6. Reaction mixtures were incubated for 3 h at room temperature under stirring.

2.2.1.2. Chitosan–thioglycolic acid conjugate (chitosan–TGA; 150 kDa). Chitosan–TGA (150 kDa) was synthesized by covalent attachment of TGA to chitosan as described previously [8]. Briefly, 1% (m/v) solution of chitosan hydrochloride was obtained by the initial hydration of 500 mg of chitosan in 4 ml of 1 M HCl followed by addition of the according volume of demineralized water. Thereafter, 500 mg of TGA was added. After TGA was completely dissolved in the chitosan hydrochloride solution, EDAC was added in a final concentration of 125 mM in order to activate the carboxylic acid moieties of TGA. The reaction mixture was incubated at pH 5 for 3 h at room temperature under stirring.

2.2.1.3. Thiolated PEG-g-PEI copolymer (PEG-g-PEI-SH; 16 kDa). Thiolated PEG-*g*-PEI copolymer was synthesized according to a method described previously [9]. In brief, 4 g of PEG were dissolved in 40 ml of chloroform followed by the addition of 36 ml of HMDI and refluxed for 48 h. The activated polymer formed was precipitated by the addition of 600 ml of petroleum ether, and the resulting solid product was re-dissolved in 15 ml of chloroform. Precipitation was repeated four times. The activated polymer was vacuum dried and weighed. A solution of 4 g of PEI 600 Da in 50 ml $CHCl_3$ was added dropwise (with continuous stirring) to a solution of 3.8 g of activated PEG in 50 ml $CHCl_3$. The mixture was refluxed for 48 h. The copolymer was precipitated by the addition of 500 ml of petroleum ether and 2.6 g of PEG-*g*-PEI copolymer were dissolved in 50 ml of distilled water. pH value was adjusted to 5.75 with 1 M HCl followed by the addition of 1000 μl of γ-thiobutyrolactone under continuous stirring for 2 h. The pH value after thiolation was 5.30.

2.2.2. Purification

In order to eliminate unbound reacting species from the polymers, each of the above four reaction mixtures was dialyzed five times using Spectra/Por® 3 membrane (MWCO: 1200) at (low acidic) pH ~ 3 according to a method described previously [10] for 3 days in total at 10 °C in the dark. In detail, the thiolated polymers were dialyzed one time against 5 mM HCl and then two times against the same medium but containing 1% NaCl, finally two times against 1 mM HCl. After dialysis, the pH of PAA–cysteine conjugates was readjusted to 6. Thereafter, the dialyzed products were freeze-dried for 3 days at −80 °C under reduced pressure and stored at 4 °C until use [11].

2.2.3. Determination of the thiol group content

The amount of thiol groups immobilized on the polymer conjugates was determined spectrophotometrically using Ellman's reagent as described previously [12]. TGA standards were used to calculate the amount of thiol groups immobilized on the chitosan–TGA conjugate while L-cysteine. HCl was employed to establish calibration curve for all other polymer conjugates.

2.2.4. CYP3A4 and CYP2A6 enzyme inhibition assays

All incubations were performed in 96-well plates, and the experimental conditions are summarized in Table 1. For CYP3A4 in each well, 150 μl of incubation medium containing 100 mM Tris–HCl buffer (pH 7.4), 4.2 mM $MgCl_2$, 50 μM 7-benzyloxy-4-(trifluoromethyl)coumarin (BFC), 0.001–1000 μM or 0.001–1.00% test substance/polymer, and 0.75 pmol cDNA expressing CYP were transferred. The reaction was initiated by the addition of 0.3 mM NADPH (50 μl) after 10 min preincubation at 37 °C. The reaction mixture was incubated at 37 °C for 30 min and terminated by the addition of 110 μl of 80% acetonitrile/20% 0.5 M Tris base. The formed fluorescence was measured using microplate reader (Tecan infinite M200 spectrophotometer, Grödig, Austria). For CYP2A6 in each well, 100 μl of incubation medium containing 75 μl of 50 mM Tris–HCl buffer (pH 7.4), 5.0 mM $MgCl_2$, 10 μM coumarin, 0.001–1000 μM or 0.001–1.00% test substance/polymer, and 0.75 pmol cDNA expressing CYP were transferred. The reaction was initiated by the addition of 0.3 mM NADPH (25 μl) and terminated by the addition of 60 μl of 10% trichloroacetic acid (TCA) after 15 min of incubation at 37 °C. Immediately before the measurement, 140 μl of 1.6 mM glycine–NaOH buffer pH 10.4 was